This Group aims to better understand the effects of cancer and treatment on health-related quality of life for patients across diverse population groups and cultures. Members develop and refine related questionnaires for oncology clinical trials, other well-designed research studies and clinical practice. They also collaborate with other EORTC research groups to implement studies in clinical trials. EORTC’s QLQ-30 questionnaire which has become one of the standard tools to measure quality of life in cancer clinical trials. The core questionnaire, currently available in over 100 languages, is accompanied by more than 20 fully-validated modules, addressing disease or population-specific concerns.


  • Quality of Life Group

    EORTC Quality of Life Group releases its QLQ-C30 questionnaire.

    EORTC Quality of Life Group developed and released a core questionnaire to assess the quality of life of cancer patients. Since then, it has been translated and validated into over 100 languages and is used in each year in more than 5,000 studies worldwide.

  • Quality of Life Group

    Health-related quality of life in survivors of locally advanced breast cancer.

    An international randomized controlled phase III trial.

    EORTC study comparing two treatment regimens (dose-intensive chemotherapy versus standard chemotherapy of a combination treatment of yclophosphamide, epirubicin and fluorouraci, prior to operation), in patients with locally advanced breast cancer. Results showed that patients assigned to dose-intensive treatment had significantly lower health-related quality of life (HRQOL) scores during the first three months, but scores returned to near baseline with no difference between groups after 12 months. This was the first randomized trial to show that dose-intensive treatment may lead to temporary reduction of HRQOL scores.

  • Quality of Life Group

    Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials.

    EORTC conducted a meta-analysis of baseline health-related quality of life (HRQOL) parameters (e.g. age, sex, distant metastases) from 30 randomized controlled trials, spanning across 11 different cancer sites. The findings suggest that HRQOL parameters and scales, when combined with socio-demographic and clinical information, provide additional prognostic information that informs treatment and can be used to help predict survival in cancer patients.

  • Gynecological Group / QoL

    EORTC 55971 – Randomized Phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy in patients with Stage IIIc or IV epithelial ovarian carcinoma.

    EORTC found that in patients with stage IIIC or IV epithelial ovarian cancer, timing of surgery (before or after chemotherapy) did not affect survival or health-related quality of life (HRQOL) in these patients. This finding helps enable clinicians to provide evidence-based information to their patient to support decision making.


  • Jan-83
  • Apr-05
  • Aug-09
  • Sep-10


Want to read in detail our scientific findings on specific tumour type?
Search through our comprehensive list of EORTC published articles to date.

Search for an article
Sign up